- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06780670
Estudo aberto comparando AAA817 versus padrão de tratamento no tratamento de adultos com mCRPC positivo para PSMA previamente tratados que apresentam progressão da doença durante ou após terapia direcionada a [177Lu] Lu-PSMA (PSMAcTION)
PSMAcTION: Um estudo de fase II/III, aberto, internacional, multicêntrico, randomizado de AAA817 versus padrão de tratamento no tratamento de participantes adultos com câncer de próstata metastático resistente à castração positivo para PSMA que progrediu em ou após [177Lu] Lu-PSMA Terapia direcionada
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after [177Lu]Lu-PSMA targeted therapy.
Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment is investigator's choice of Standard of Care, regardless of subsequent anti-neoplastic treatment
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Study CAAA817A12201 consists of 2 parts: a randomized, open-label, international, multicenter, phase II study (Phase II) to collect more information to support the proposed dose of AAA817 and a randomized, open-label, international, multicenter, 2- arm phase III study (Phase III) aimed to evaluate the efficacy and safety of proposed dose of AAA817 vs. investigator's choice of standard of care (SoC) in the treatment of adult participants with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who had treatments with ARPI and taxane-based chemotherapy, and progressed on or after [177Lu]Lu-PSMA targeted therapy. The purpose of the phase II part (Phase II) of this study is to collect additional information to support proposed phase III dose of AAA817.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: Novartis Pharmaceuticals
- Número de telefone: 1-888-669-6682
- E-mail: novartis.email@novartis.com
Estude backup de contato
- Nome: Novartis Pharmaceuticals
- Número de telefone: +41613241111
Locais de estudo
-
-
New South Wales
-
Darlinghurst, New South Wales, Austrália, 2010
- Recrutamento
- Novartis Investigative Site
-
-
Queensland
-
Herston, Queensland, Austrália, 4029
- Recrutamento
- Novartis Investigative Site
-
-
Victoria
-
Melbourne, Victoria, Austrália, 3004
- Recrutamento
- Novartis Investigative Site
-
-
-
-
São Paulo
-
São Paulo, São Paulo, Brasil, 01308-050
- Recrutamento
- Novartis Investigative Site
-
São Paulo, São Paulo, Brasil, 05652-000
- Recrutamento
- Novartis Investigative Site
-
-
-
-
-
Beijing, China, 100036
- Recrutamento
- Novartis Investigative Site
-
Beijing, China, 100034
- Recrutamento
- Novartis Investigative Site
-
Guangzhou, China, 510060
- Recrutamento
- Novartis Investigative Site
-
Shanghai, China, 200025
- Recrutamento
- Novartis Investigative Site
-
Shanghai, China, 200032
- Recrutamento
- Novartis Investigative Site
-
Tianjin, China, 300480
- Recrutamento
- Novartis Investigative Site
-
Tianjin, China, 300300
- Recrutamento
- Novartis Investigative Site
-
-
Fujian
-
Fuzhou, Fujian, China, 350025
- Recrutamento
- Novartis Investigative Site
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Recrutamento
- Novartis Investigative Site
-
Wuhan, Hubei, China, 430030
- Recrutamento
- Novartis Investigative Site
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210006
- Recrutamento
- Novartis Investigative Site
-
Nanjing, Jiangsu, China, 210029
- Recrutamento
- Novartis Investigative Site
-
-
Liaoning
-
Shenyang, Liaoning, China, 110011
- Recrutamento
- Novartis Investigative Site
-
-
Shanxi
-
Xian, Shanxi, China, 710032
- Recrutamento
- Novartis Investigative Site
-
Xian, Shanxi, China, 710061
- Recrutamento
- Novartis Investigative Site
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recrutamento
- Novartis Investigative Site
-
-
-
-
-
Singapore, Cingapura, 119228
- Recrutamento
- Novartis Investigative Site
-
Singapore, Cingapura, 168583
- Recrutamento
- Novartis Investigative Site
-
Singapore, Cingapura, 258499
- Recrutamento
- Novartis Investigative Site
-
-
-
-
-
Seoul, Coréia do Sul, 03080
- Recrutamento
- Novartis Investigative Site
-
Seoul, Coréia do Sul, 05505
- Recrutamento
- Novartis Investigative Site
-
Seoul, Coréia do Sul, 06591
- Recrutamento
- Novartis Investigative Site
-
Seoul, Coréia do Sul, 03722
- Recrutamento
- Novartis Investigative Site
-
-
-
-
Arizona
-
Scottsdale, Arizona, Estados Unidos, 85258
- Recrutamento
- Honor Health Research Institute
-
Investigador principal:
- Michael Gordon
-
Contato:
- Cierra Spikes
- E-mail: cspikes@honorhealth.com
-
-
California
-
Los Angeles, California, Estados Unidos, 90073
- Recrutamento
- VA Greater LA Healthcare System
-
Contato:
- Janake Wijesuriya
- E-mail: janake.wijesuriya@va.gov
-
Investigador principal:
- Gholam Reza Berenji
-
Palo Alto, California, Estados Unidos, 94304-1207
- Recrutamento
- VA Palo Alto Health Care System
-
Investigador principal:
- Minal Vasanawala
-
Contato:
- Pallavi Gautam
- Número de telefone: 650-493-5000
- E-mail: pallavi.gautam@va.gov
-
Palo Alto, California, Estados Unidos, 94304
- Recrutamento
- Stanford University Medical Center
-
Investigador principal:
- Hong Song
-
Contato:
- Mikayla Easterling
- E-mail: maeast@stanford.edu
-
Santa Barbara, California, Estados Unidos, 93105
- Recrutamento
- Sansum Clinic
-
Investigador principal:
- Gregg Newman
-
Contato:
- Jessica Wong
- Número de telefone: 805-563-5800
- E-mail: jessica.wong2@sutterhealth.org
-
Santa Monica, California, Estados Unidos, 90404
- Recrutamento
- Saint Johns Cancer Institute
-
Investigador principal:
- Przemyslaw Twardowski
-
Contato:
- Joey Dumadag
- Número de telefone: 310-829-8569
- E-mail: joey.dumadag@providence.org
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80218
- Recrutamento
- Rocky Mountain Cancer Centers
-
Investigador principal:
- Manojkumar Bupathi
-
Contato:
- Jannae Foellmer
- Número de telefone: 303-385-2000
- E-mail: jannae.foellmer@usoncology.com
-
-
Connecticut
-
Hartford, Connecticut, Estados Unidos, 06102
- Recrutamento
- Hartford Hospital
-
Investigador principal:
- Andrew Salner
-
Contato:
- Melanie Manning
- E-mail: Melanie.Manning@hhchealth.org
-
-
Florida
-
Miami, Florida, Estados Unidos, 33173
- Recrutamento
- Baptist Health South
-
Investigador principal:
- Adeel Kaiser
-
Contato:
- Leslie Castaneda
- E-mail: leslie.castaneda@baptisthealth.net
-
Orlando, Florida, Estados Unidos, 32804
- Recrutamento
- AdventHealth
-
Investigador principal:
- Ravi Shridhar
-
Contato:
- Joseph Guzzo
- Número de telefone: 407-303-3235
- E-mail: joseph.guzzo@adventhealth.com
-
-
Georgia
-
Athens, Georgia, Estados Unidos, 30607
- Recrutamento
- University Cancer and Blood Center LLC
-
Contato:
- Christen Nicole Cooper Pope
- Número de telefone: +1 706 353 2990
- E-mail: npope@universitycancer.com
-
Investigador principal:
- Petros Nikolinakos
-
Atlanta, Georgia, Estados Unidos, 30322
- Recrutamento
- Emory University
-
Investigador principal:
- Shahid Sattar Ahmed
-
Contato:
- Jalpa Patel
- Número de telefone: +1 404 778 1835
- E-mail: jalpa.r.patel@emory.edu
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- Recrutamento
- University of Chicago
-
Investigador principal:
- Mohammad Atiq
-
Contato:
- Paige Olson
- Número de telefone: 773-702-4848
- E-mail: paige.olson@bsd.uchicago.edu
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Recrutamento
- Indiana University
-
Investigador principal:
- Nabil Adra
-
Contato:
- Marie Burton
- E-mail: mariburt@iu.edu
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- Recrutamento
- University of Kansas Hospital
-
Investigador principal:
- Xinglei Shen
-
Contato:
- Kelsey Schwensen
- E-mail: kschwensen@kumc.edu
-
-
Louisiana
-
Metairie, Louisiana, Estados Unidos, 70006
- Recrutamento
- East Jefferson Hospital
-
Investigador principal:
- Alton Oliver Sartor
-
Contato:
- Alexandra Lieberman
- E-mail: alexandra.lieberman@lcmchealth.org
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Recrutamento
- Beth Israel Deaconess Medical Center
-
Investigador principal:
- David J Einstein
-
Contato:
- Ooviya Sathiyamoorthy
- Número de telefone: 617-643-9923
- E-mail: osathiya@bidmc.harvard.edu
-
Boston, Massachusetts, Estados Unidos, 02115
- Recrutamento
- Dana Farber Cancer Institute
-
Investigador principal:
- Xiao Wei
-
Contato:
- Michael Bonhomme
- Número de telefone: 617-632-5136
- E-mail: michael_bonhomme@dfci.harvard.edu
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Recrutamento
- WA Uni School Of Med
-
Investigador principal:
- Jeff Michalski
-
Contato:
- Collin Welch
- Número de telefone: 314-454-8293
- E-mail: c.welch@wustl.edu
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68154
- Recrutamento
- Nebraska Cancer Specialists
-
Investigador principal:
- Samuel Mehr
-
Contato:
- Marlene Bridwell
- Número de telefone: 402-334-4773
- E-mail: mbridwell@nebraskacancer.com
-
-
New Jersey
-
Voorhees Township, New Jersey, Estados Unidos, 08043
- Recrutamento
- New Jersey Urology LLC
-
Contato:
- Gabriela Mercado
- Número de telefone: 856-673-1613
- E-mail: gmercado3@nj-urology.com
-
Investigador principal:
- Gordon Brown
-
-
New York
-
New York, New York, Estados Unidos, 10029
- Recrutamento
- Mount Sinai Hosp Med School
-
Investigador principal:
- Randy Yeh
-
Contato:
- Ilda Bander
- Número de telefone: 212-241-8903
- E-mail: Ilda.Bander@mountsinai.org
-
Syracuse, New York, Estados Unidos, 13210
- Recrutamento
- Associated Med Professionals of NY
-
Investigador principal:
- Steven Finkelstein
-
Contato:
- Nathan Forrest
- E-mail: nathan.forrest@ampofny.com
-
The Bronx, New York, Estados Unidos, 10467
- Recrutamento
- Montefiore Medical Center
-
Investigador principal:
- Benjamin A Gartrell
-
Contato:
- Tahrima Chowdhury
- Número de telefone: 718-920-6642
- E-mail: tahchowdhu@montefiore.org
-
-
Ohio
-
Gahanna, Ohio, Estados Unidos, 43230
- Recrutamento
- Central Ohio Urology Group
-
Investigador principal:
- Benjamin Martin
-
Contato:
- Sarah Faisal
- E-mail: sarah.faisal@us-uro.com
-
-
Oregon
-
Springfield, Oregon, Estados Unidos, 97477
- Recrutamento
- Oregon Urology Institute
-
Investigador principal:
- Bryan Mehlhaff
-
Contato:
- Maxim Dimarco
- E-mail: mdimarco@oregonurology.com
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19111
- Recrutamento
- Fox Chase Cancer Center
-
Contato:
- Candice Schewbel
- Número de telefone: 215-728-3075
- E-mail: candice.schwebel@fccc.edu
-
Investigador principal:
- Matthew Zibelman
-
-
South Carolina
-
Myrtle Beach, South Carolina, Estados Unidos, 29572
- Recrutamento
- Carolina Urologic Research Center
-
Investigador principal:
- Neal D Shore
-
Contato:
- Rebecca Floyd
- Número de telefone: 843-839-1679
- E-mail: rebecca.floyd@startresearch.com
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75251
- Recrutamento
- Texas Oncology
-
Contato:
- Marian Heaven
- Número de telefone: 512-427-9467
- E-mail: marian.heaven@usoncology.com
-
Investigador principal:
- Michael P Herman
-
San Antonio, Texas, Estados Unidos, 78229
- Recrutamento
- Urology San Antonio
-
Investigador principal:
- Daniel Saltzstein
-
Contato:
- Sandra Davila
- E-mail: sandra.davila@usa-clinicaltrials.com
-
-
Utah
-
Murray, Utah, Estados Unidos, 84107
- Recrutamento
- Utah Intermountain Medical Center
-
Investigador principal:
- David Gill
-
Contato:
- Becky Arroyo
- E-mail: becky.arroyo@imail.org
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Recrutamento
- Virginia Cancer Specialists
-
Investigador principal:
- Gregory Scott Sibley
-
Contato:
- Kristi Ben-Barka
- E-mail: kristi.ben-barka@usoncology.com
-
Roanoke, Virginia, Estados Unidos, 24014
- Recrutamento
- Onco Hemato Asso of SW Virginia
-
Investigador principal:
- David Buck
-
Contato:
- Natasha Holt
- Número de telefone: 540-774-8660
- E-mail: natasha.holt@usoncology.com
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109-1024
- Recrutamento
- Fred Hutchinson Cancer Research Center
-
Contato:
- Brianna Woo
- E-mail: bwoo@fredhutch.org
-
Investigador principal:
- Ruben Raychaudhuri
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Recrutamento
- Medical College Of Wisconsin
-
Investigador principal:
- Deepak Kilari
-
Contato:
- Nadia Thomas
- E-mail: nathomas@mcw.edu
-
-
-
-
-
Hong Kong, Hong Kong, 999077
- Recrutamento
- Novartis Investigative Site
-
-
-
-
-
Beersheba, Israel, 8457108
- Recrutamento
- Novartis Investigative Site
-
Haifa, Israel, 3109601
- Recrutamento
- Novartis Investigative Site
-
Jerusalem, Israel, 9112001
- Recrutamento
- Novartis Investigative Site
-
Petah Tikva, Israel, 4941492
- Recrutamento
- Novartis Investigative Site
-
Ramat Gan, Israel, 5265601
- Recrutamento
- Novartis Investigative Site
-
Tel Aviv, Israel, 6423906
- Recrutamento
- Novartis Investigative Site
-
-
-
-
-
Chiba, Japão, 2608717
- Recrutamento
- Novartis Investigative Site
-
Fukuoka, Japão, 8128582
- Recrutamento
- Novartis Investigative Site
-
Fukuoka, Japão, 8110213
- Recrutamento
- Novartis Investigative Site
-
Fukuoka, Japão, 8120033
- Recrutamento
- Novartis Investigative Site
-
Fukushima, Japão, 9601295
- Recrutamento
- Novartis Investigative Site
-
Ishikawa, Japão, 9208641
- Recrutamento
- Novartis Investigative Site
-
Kyoto, Japão, 6068507
- Recrutamento
- Novartis Investigative Site
-
-
Chiba
-
Kashiwa, Chiba, Japão, 2778577
- Recrutamento
- Novartis Investigative Site
-
-
Hokkaido
-
Sapporo, Hokkaido, Japão, 0608648
- Recrutamento
- Novartis Investigative Site
-
-
Hyōgo
-
Kobe, Hyōgo, Japão, 6500047
- Recrutamento
- Novartis Investigative Site
-
-
Kanagawa
-
Yokohama, Kanagawa, Japão, 2360004
- Recrutamento
- Novartis Investigative Site
-
-
-
-
Kuala Lumpur
-
Putrajaya, Kuala Lumpur, Malásia, 62250
- Recrutamento
- Novartis Investigative Site
-
-
Selangor
-
Petaling Jaya, Selangor, Malásia, 46050
- Recrutamento
- Novartis Investigative Site
-
Petaling Jaya, Selangor, Malásia, 46150
- Recrutamento
- Novartis Investigative Site
-
-
-
-
-
Huxquilucan, México, 52763
- Recrutamento
- Novartis Investigative Site
-
-
Mexico City
-
Mexico City, Mexico City, México, 14050
- Recrutamento
- Novartis Investigative Site
-
-
-
-
-
Basel, Suíça, 4031
- Recrutamento
- Novartis Investigative Site
-
Bellinzona, Suíça, 6500
- Recrutamento
- Novartis Investigative Site
-
Bern, Suíça, 3010
- Recrutamento
- Novartis Investigative Site
-
-
-
-
-
Taipei, Taiwan, 10002
- Recrutamento
- Novartis Investigative Site
-
Taipei, Taiwan, 11217
- Recrutamento
- Novartis Investigative Site
-
Taipei, Taiwan, 103616
- Recrutamento
- Novartis Investigative Site
-
Taoyuan, Taiwan, 33305
- Recrutamento
- Novartis Investigative Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria: ∙
- adults ≥ 18 years of age.
- ECOG performance status of 0 to 2.
- histopathological and/or cytological confirmation of adenocarcinoma of the prostate.
- PSMA-positive disease as assessed by PSMA PET/CT scan using an approved PSMA imaging agent as protocol instructed,
- castrate level of serum/plasma testosterone (< 50 ng/dL or < 1.7 nmol/L).
- Prior treatments with an androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy, and progressed on or after [177Lu]Lu-PSMA targeted therapy.
- ≥ 1 metastatic lesion that is present on screening/baseline CT, MRI, or bone scan imaging obtained ≤ 28 days prior to randomization
- eGFR as requested by the sponsor
Exclusion Criteria:
- Any investigational agents within 28 days prior to the day of randomization.
- Any 225Ac-based investigational compound used prior to the day of randomization.
- Participants with a history of CNS metastases who are neurologically unstable, symptomatic, or receiving corticosteroids for the purpose of maintaining neurologic integrity.
- Concurrent acute kidney injury (renal failure developed between 48 hours to 7 days) or chronic kidney disease (at least 3 months of ongoing renal injury)
- Baseline xerostomia ≥ Grade 2 by CTCAE v.5
- History of uncontrolled hypertension, myocardial infarction (MI), angina pectoris, or coronary artery bypass graft (CABG) within 6 months prior to ICF signature and/or clinically active significant cardiac disease
- History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 2 years (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months, non-invasive malignant colon polyps that have been removed).
Other protocol-defined inclusion/exclusion criteria may apply.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Phase II: AAA817 Dose B
AAA817 will be given for a number of cycles; a cycle = 8 weeks |
The investigational treatment is AAA817
Outros nomes:
Investigational treatment is the Dose B of AAA817
Outros nomes:
|
|
Comparador Ativo: Phase III: Investigator's choice of SoC
Participants will be given Standard of Care (SOC) treatment per Investigator's choice. |
The control treatment in Phase III is investigator's choice of SoC |
|
Experimental: Phase II: AAA817 Dose A
AAA817 Dose A will be given for a number of cycles: a cycle = 8 weeks |
The investigational treatment is AAA817
Outros nomes:
Investigational treatment is the Dose B of AAA817
Outros nomes:
|
|
Experimental: Phase III: Recommended Phase 3 Dose of AAA817
Rp3D of AAA817 will be given for a number of cycles; a cycle = 8 weeks |
The investigational treatment is AAA817
Outros nomes:
Investigational treatment is the Dose B of AAA817
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Biochemical response rate (Phase II)
Prazo: from date of randomization up to approximately 24 months
|
Biochemical response rate as defined as the percentage of participants who achieved a ≥ 50% decrease from baseline that is confirmed by a second measurement |
from date of randomization up to approximately 24 months
|
|
Adverse Events (AEs) and Serious Adverse Events (SAEs), and deaths - Phase II
Prazo: from day of randomization to 30 days after End of Treatment or (last AAA817 dose date + 55 days, last dose date of SoC + 30 days), whichever is later
|
Safety defined as the type, incidence and severity of AEs and SAEs, and deaths |
from day of randomization to 30 days after End of Treatment or (last AAA817 dose date + 55 days, last dose date of SoC + 30 days), whichever is later
|
|
Tolerability of the proposed dose of AAA817- Phase II
Prazo: From on-treatment period which start from the first dose of study treatment until 30 days post-last dose date for SoC and 55 days post last-dose for AAA817
|
Percentage of participants who experienced Dose interruptions, reductions, discontinuation, dose intensity and duration of exposure |
From on-treatment period which start from the first dose of study treatment until 30 days post-last dose date for SoC and 55 days post last-dose for AAA817
|
|
Radiographic progression-free survival (rPFS)- Phase III
Prazo: from date of randomization up to approximately 24 months
|
Percentage of participants who are alive without radiographic progression or who are lost to follow-up at the time of analysis |
from date of randomization up to approximately 24 months
|
|
Overall survival (OS)- Phase III
Prazo: from date of randomization up to approximately 24 months
|
Percentage of participants who are alive or who are lost to follow-up at the time of analysis |
from date of randomization up to approximately 24 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Radiographic progression-free survival (rPFS)- Phase II
Prazo: from date of randomization up to approximately 24 months
|
Percentage of participants who are alive without radiographic progression or who are lost to follow-up at the time of analysis |
from date of randomization up to approximately 24 months
|
|
Progression free survival (PFS)- Phase II
Prazo: from date of randomization up to approximately 24 months
|
Percentage of Participants meeting Progression Free Survival |
from date of randomization up to approximately 24 months
|
|
Overall response rate (ORR)- Phase II
Prazo: from date of randomization up to approximately 24 months
|
Percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) |
from date of randomization up to approximately 24 months
|
|
Disease control rate (DCR)- Phase II
Prazo: from date of randomization up to approximately 24 months
|
Percentage of participants with BOR of CR, PR, stable disease (SD) or non-CR/non-PD |
from date of randomization up to approximately 24 months
|
|
Overall survival (OS)- Phase II
Prazo: from date of randomization up to approximately 24 months
|
Percentage of participants who are alive or who are lost to follow-up at the analysis data cut-off |
from date of randomization up to approximately 24 months
|
|
Progression free survival (PFS) -Phase III
Prazo: from date of randomization up to approximately 24 months
|
Percentage of participants with PFS -defined as the time from date of randomization to first documented progression |
from date of randomization up to approximately 24 months
|
|
Overall response rate (ORR)- Phase III
Prazo: from date of randomization up to approximately 24 months
|
ORR is defined as the percentage of participants with best overall response (BOR) of confirmed complete response (CR) or partial response (PR) |
from date of randomization up to approximately 24 months
|
|
Disease control rate (DCR) -Phase III
Prazo: from date of randomization up to approximately 24 months
|
DCR is defined as the percentage of participants with BOR of confirmed CR, PR, stable disease (SD) or Non-CR/Non progressive disease (PD) |
from date of randomization up to approximately 24 months
|
|
Duration of response (DoR)- Phase III
Prazo: from date of randomization up to approximately 24 months
|
Percentage of participants with confirmed DoR defined as duration of time between the date of first documented response (CR or PR) and progression or death due to any cause, whichever occurs first. |
from date of randomization up to approximately 24 months
|
|
Time to first radiographic soft tissue progression (TTSTP)- Phase III
Prazo: from date of randomization up to approximately 24 months
|
Percentage of participants with confirmed first radiographic progression in soft tissue |
from date of randomization up to approximately 24 months
|
|
First symptomatic skeletal event (TTSSE)_Phase III
Prazo: from date of randomization up to approximately 24 months
|
Percentage of participants with confirmed skeletal event is defined as new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, or requirement for radiation therapy to relieve bone pain, or death due to any cause, whichever occurs first |
from date of randomization up to approximately 24 months
|
|
Prostate specific antigen (PSA) response -Phase III
Prazo: from date of randomization up to approximately 24 months
|
PSA50 is defined as the percentage of participants who achieved a confirmed ≥ 50% decrease from baseline |
from date of randomization up to approximately 24 months
|
|
Patient reported disease related symptoms and health-related quality of life (HRQoL): Phase III
Prazo: from date of randomization up to approximately 24 months
|
Percentage of participants who had a Change from baseline on FACT-P Prostate Cancer Subscale (PCS) |
from date of randomization up to approximately 24 months
|
|
Time to worsening on the Worst Pain: Phase III
Prazo: from date of randomization up to approximately 24 months
|
Time to worsening on the Worst Pain defined as the time from randomization to the first occurrence of worsening on the Worst Pain item (brief pain inventory - short form (BPI-SF)) of at least 30% of baseline or minimum of 2 points increase from baseline, or death due to any cause, whichever occurs first. BPI-SF is a self-reported questionnaire to evaluate pain intensity (severity) and impact of pain on the participant's daily functioning (interference). |
from date of randomization up to approximately 24 months
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CAAA817A12201
- 2024-512342-42-00 (Outro identificador: EU CTIS)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .